[
  {
    "ts": null,
    "headline": "Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study",
    "summary": "MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.",
    "url": "https://finnhub.io/api/news?id=908076479ac0577d11ea4f1875a39845e1f30879e5a3ad0d4e4f290650a2f6d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763567520,
      "headline": "Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study",
      "id": 137548653,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.",
      "url": "https://finnhub.io/api/news?id=908076479ac0577d11ea4f1875a39845e1f30879e5a3ad0d4e4f290650a2f6d5"
    }
  },
  {
    "ts": null,
    "headline": "Astrocytoma Market Research and Forecast Report 2025-2035: Merck and Oblato are Spearheading Advancements in Drug R&D, Addressing the Growing Demand for Enhanced Therapeutic Options",
    "summary": "The global astrocytoma market is poised for significant growth, anticipated to achieve substantial valuation by 2025 and expanding at a healthy CAGR from 2025 to 2035. This expansion is driven by the rising prevalence of high-grade astrocytomas and the increasing demand for effective treatments, including innovative immunotherapies and targeted therapies. Key growth areas include emerging markets such as Asia-Pacific, Latin America, and the Middle East, where healthcare improvements are rapidly",
    "url": "https://finnhub.io/api/news?id=51767d90842c9e4d6f27cc29cc1a516ab95c24ca8920be3a73f1132973edb557",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763564820,
      "headline": "Astrocytoma Market Research and Forecast Report 2025-2035: Merck and Oblato are Spearheading Advancements in Drug R&D, Addressing the Growing Demand for Enhanced Therapeutic Options",
      "id": 137548724,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global astrocytoma market is poised for significant growth, anticipated to achieve substantial valuation by 2025 and expanding at a healthy CAGR from 2025 to 2035. This expansion is driven by the rising prevalence of high-grade astrocytomas and the increasing demand for effective treatments, including innovative immunotherapies and targeted therapies. Key growth areas include emerging markets such as Asia-Pacific, Latin America, and the Middle East, where healthcare improvements are rapidly",
      "url": "https://finnhub.io/api/news?id=51767d90842c9e4d6f27cc29cc1a516ab95c24ca8920be3a73f1132973edb557"
    }
  },
  {
    "ts": null,
    "headline": "Metrorrhagia Market Analysis Report 2025-2035, Profiles of Pfizer, Sandoz, Bayer, Actavis Pharma, Noven Pharmaceuticals, Theramex, Pantarhei Bioscience, AbbVie, Neurocrine Biosciences, Merck",
    "summary": "The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula",
    "url": "https://finnhub.io/api/news?id=912accfef980ebe7e2951d98238df0e4ae3b145a019baac2f55f9a8f0bbfc50f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763562720,
      "headline": "Metrorrhagia Market Analysis Report 2025-2035, Profiles of Pfizer, Sandoz, Bayer, Actavis Pharma, Noven Pharmaceuticals, Theramex, Pantarhei Bioscience, AbbVie, Neurocrine Biosciences, Merck",
      "id": 137546410,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula",
      "url": "https://finnhub.io/api/news?id=912accfef980ebe7e2951d98238df0e4ae3b145a019baac2f55f9a8f0bbfc50f"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK): Is There Still Value After the Recent Share Price Rally?",
    "summary": "Merck (MRK) shares have ticked higher this week, catching the interest of investors who follow the big names in healthcare. The company's performance over the past month has been relatively steady. This stability invites a closer look at what might be driving sentiment. See our latest analysis for Merck. Merck’s momentum has picked up noticeably with a 1-month share price return of 13.7%, even as the year-to-date performance remains slightly negative. The stock’s 1-year total shareholder...",
    "url": "https://finnhub.io/api/news?id=75af11a2abe374a46ded018384c5606b4c92f2a9473ef8027da21bd5ea16dd4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763561879,
      "headline": "Merck (MRK): Is There Still Value After the Recent Share Price Rally?",
      "id": 137546497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) shares have ticked higher this week, catching the interest of investors who follow the big names in healthcare. The company's performance over the past month has been relatively steady. This stability invites a closer look at what might be driving sentiment. See our latest analysis for Merck. Merck’s momentum has picked up noticeably with a 1-month share price return of 13.7%, even as the year-to-date performance remains slightly negative. The stock’s 1-year total shareholder...",
      "url": "https://finnhub.io/api/news?id=75af11a2abe374a46ded018384c5606b4c92f2a9473ef8027da21bd5ea16dd4e"
    }
  },
  {
    "ts": null,
    "headline": "SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK",
    "summary": "GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the",
    "url": "https://finnhub.io/api/news?id=44f3878d657d9f80e8a57464fd38a487ee24b274d46b0ba2fb141adc2a5c90af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763553600,
      "headline": "SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK",
      "id": 137546498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the",
      "url": "https://finnhub.io/api/news?id=44f3878d657d9f80e8a57464fd38a487ee24b274d46b0ba2fb141adc2a5c90af"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection",
    "summary": "RAHWAY, N.J., November 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg)] in adults with HIV-1 infection who had not previously received antiretroviral treatment (treatment-naïve) (MK-8591A-053). The success criterion for the primary efficacy hypothesis, as measured",
    "url": "https://finnhub.io/api/news?id=be39561df6d7a6889685da1285322b43276ca839b4e137398ccc8ccff32d72cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763552700,
      "headline": "Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection",
      "id": 137546499,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg)] in adults with HIV-1 infection who had not previously received antiretroviral treatment (treatment-naïve) (MK-8591A-053). The success criterion for the primary efficacy hypothesis, as measured",
      "url": "https://finnhub.io/api/news?id=be39561df6d7a6889685da1285322b43276ca839b4e137398ccc8ccff32d72cf"
    }
  },
  {
    "ts": null,
    "headline": "European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union",
    "summary": "RAHWAY, N.J., November 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved a new subcutaneous (SC), or under the skin, route of administration and a new pharmaceutical form (solution for injection) of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. KEYTRUDA SC™, as it will be marketed in the European Union (EU), [known as KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa-pmph) in the U.S.]",
    "url": "https://finnhub.io/api/news?id=d3d1454084c4c615522d417c1c5e799c26004f1bc8288223cf7aca8d031c2540",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763551800,
      "headline": "European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union",
      "id": 137546500,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved a new subcutaneous (SC), or under the skin, route of administration and a new pharmaceutical form (solution for injection) of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. KEYTRUDA SC™, as it will be marketed in the European Union (EU), [known as KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa-pmph) in the U.S.]",
      "url": "https://finnhub.io/api/news?id=d3d1454084c4c615522d417c1c5e799c26004f1bc8288223cf7aca8d031c2540"
    }
  },
  {
    "ts": null,
    "headline": "Why VYM Is Not A Good Alternative To SCHD",
    "summary": "Discover top US dividend ETFs: Compare VYM vs SCHD for stable yields, growth, and income strategies amid market shifts.",
    "url": "https://finnhub.io/api/news?id=c5563932ada62abe02044bdccad8e3c11fead5a0c21a2908596d047781c4da32",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763542800,
      "headline": "Why VYM Is Not A Good Alternative To SCHD",
      "id": 137546014,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1990349253/image_1990349253.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover top US dividend ETFs: Compare VYM vs SCHD for stable yields, growth, and income strategies amid market shifts.",
      "url": "https://finnhub.io/api/news?id=c5563932ada62abe02044bdccad8e3c11fead5a0c21a2908596d047781c4da32"
    }
  },
  {
    "ts": null,
    "headline": "Top Income And AI Growth Stocks Worth Watching",
    "summary": "Markets appear to be at an inflection point. Will AI stocks rebound, or will volatility linger? Here are three income and three AI plays for either scenario.",
    "url": "https://finnhub.io/api/news?id=483df32cad4194fa8c88fba838fbc44f85e97629481762726eada2a3de40d654",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763528400,
      "headline": "Top Income And AI Growth Stocks Worth Watching",
      "id": 137544927,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209914068/image_2209914068.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Markets appear to be at an inflection point. Will AI stocks rebound, or will volatility linger? Here are three income and three AI plays for either scenario.",
      "url": "https://finnhub.io/api/news?id=483df32cad4194fa8c88fba838fbc44f85e97629481762726eada2a3de40d654"
    }
  },
  {
    "ts": null,
    "headline": "Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying",
    "summary": "I'm rating Summit Therapeutics a 'cautious Buy' based on the promising dual-action lung cancer therapy Ivonescimab and significant insider buying.",
    "url": "https://finnhub.io/api/news?id=bd6fc09d311a6b69d44e8387a9a2dea4a4ec31b0cb6662c18963e7319db8f81f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763526394,
      "headline": "Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying",
      "id": 137544759,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2181187387/image_2181187387.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "I'm rating Summit Therapeutics a 'cautious Buy' based on the promising dual-action lung cancer therapy Ivonescimab and significant insider buying.",
      "url": "https://finnhub.io/api/news?id=bd6fc09d311a6b69d44e8387a9a2dea4a4ec31b0cb6662c18963e7319db8f81f"
    }
  },
  {
    "ts": null,
    "headline": "Deutsche Bank Maintains Merck (MRK) Hold Recommendation",
    "summary": "Deutsche Bank Maintains Merck (MRK) Hold Recommendation",
    "url": "https://finnhub.io/api/news?id=531d7d05d0e7a4a896d167e66525697f3273a0b210fb3c0faf61a86c64e6dfad",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763510698,
      "headline": "Deutsche Bank Maintains Merck (MRK) Hold Recommendation",
      "id": 137541561,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=531d7d05d0e7a4a896d167e66525697f3273a0b210fb3c0faf61a86c64e6dfad"
    }
  }
]